Ruggero Cascio Ingurgio

Dr. Ruggero Cascio Ingurgio

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2025 in Australasian Journal of Dermatology
Verified
Journal Article
Open access
RIRuggero Cascio Ingurgio
Ruggero Cascio Ingurgio
AAA. Alfano
A. Alfano
EME. Matteodo
E. Matteodo
MSM. Stark
M. Stark
MVM. Valenti
M. Valenti
Dedee MurrellDedee Murrell
Dedee Murrell
Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with systemic implications. While biologic therapies have demonstrated efficacy in controlling cutaneous lesions, their systemic effects, particularly on lipid metabolism as a marker of systemic inflammation, are less understood. Objectives: To evaluate the impact of biologic therapy on clinical severity and lipid profiles in HS patients in a real‐world setting, comparing outcomes between Early and Late Responders at Week 24 ± 4. Methods: Twenty‐four patients with moderate‐to‐severe HS on biologic therapy were monitored prospectively at Baseline, Week 24 ± 4, Week 52 and Week 104. Clinical parameters (IHS4, A/N, HS‐IGA) and lipid profiles (cholesterol, triglycerides) were analysed. Patients were categorised as Early (IHS4 ≤ 10) or Late Responders (IHS4 ≥ 11) at Week 24 ± 4. Statistical analysis included t ‐tests; significance was set at p < 0.05. Results: Early Responders showed significant clinical improvement and reductions in lipid levels, suggesting a systemic anti‐inflammatory effect of therapy. However, lipid reductions did not reach statistical significance ( p > 0.05); likely due to the small sample size. Late Responders demonstrated less pronounced changes. Conclusions: Biologic therapy appears to improve both clinical and systemic inflammatory markers in HS, highlighting the value of metabolic monitoring in routine care.

20 August 2025 in International Journal of Dermatology
Verified
Journal Article
Open access
LPLuca Potestio
Luca Potestio
Cataldo PatrunoCataldo Patruno
Cataldo Patruno
MGMarika Del Gaudio
Marika Del Gaudio
MOMichela Ortoncelli
Michela Ortoncelli
SRSimone Ribero
Simone Ribero
Maddalena NapolitanoMaddalena Napolitano
Maddalena Napolitano
Background: Conjunctivitis is among the most frequent adverse events (AEs) emerged in clinical trials for all biologic drugs approved for atopic dermatitis (AD). However, real‐world comparative data on the incidence, risk factors, and management of conjunctivitis remain limited. Objective: We aimed to compare the incidence, clinical features, and management of conjunctivitis in patients with moderate‐to‐severe AD treated with dupilumab or tralokinumab in a real‐life setting. Patients and Methods: A multicenter, retrospective, observational study including adult patients with moderate‐to‐severe AD treated with dupilumab or tralokinumab for at least 16 weeks was carried out. Demographic, clinical, and therapeutic data were collected from 35 dermatological referral centers across Italy. Conjunctivitis incidence, severity, time to onset, and ophthalmologic management were analyzed and compared between treatment groups. Results: A total of 6668 patients were included (5899 on dupilumab and 769 on tralokinumab). Conjunctivitis occurred in 10.76% of dupilumab‐treated and 12.61% of tralokinumab‐treated patients, with no statistically significant difference in overall incidence. However, time to onset was significantly shorter with tralokinumab than with dupilumab (15.3 ± 14.5 weeks vs. 35.5 ± 45.2 weeks, respectively; p < 0.0001). Ophthalmologic management strategies were similar between groups, mainly involving lubricants and corticosteroid‐based eye drops. Dupilumab‐treated patients more frequently discontinued or switched treatment due to conjunctivitis than tralokinumab patients (25.4% vs. 14.4%, respectively; p < 0.05). Conclusions: Conjunctivitis represents a relatively frequent AE in patients with AD receiving dupilumab or tralokinumab. However, earlier onset of conjunctivitis with tralokinumab and higher discontinuation rates with dupilumab suggest differing tolerability profiles. Early recognition of ocular symptoms is essential, and dermatologists should promptly initiate supportive eye care and refer to ophthalmologists when appropriate to avoid unnecessary treatment interruptions.

1 June 2026 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
RIRuggero Cascio Ingurgio
Ruggero Cascio Ingurgio
AAAngela Alfano
Angela Alfano
ACAntonio Costanzo
Antonio Costanzo
JCJulie S. Cronk
Julie S. Cronk
RCRebecca Cummins
Rebecca Cummins
Dedee MurrellDedee Murrell
Dedee Murrell
Background: Isotretinoin is the most effective treatment for severe acne, but optimal cumulative dosing remains debated. While 120 mg/kg is standard, some advocate higher doses or prolonged treatment to reduce relapse. Objectives: To compare acne outcomes between 120 and 150 mg/kg cumulative isotretinoin dosing and to evaluate 12‐month relapse and scarring. Methods: In this single‐centre, randomized single‐blind trial, with blinded outcomes assessment, patients with moderate‐to‐severe cystic acne were allocated to cumulative isotretinoin doses of 120 or 150 mg/kg. Primary outcomes were changes in total lesion count and acne severity grade (1–8 scale) from baseline to mid‐treatment and end of treatment; secondary outcomes included 12‐month acne relapse and scarring. Results: Both cumulative dose groups showed comparable improvements in acne severity and lesion counts from baseline to treatment completion, with no significant differences between groups (all p > 0.20). Scarring did not worsen over the course of treatment. At 12 months after treatment discontinuation, relapse rates were similar between groups: 26.7% in the 120 mg/kg group and 32.3% in the 150 mg/kg group ( p = 0.619). Adverse events were mild and comparable. Limitations: Single‐centre design and retrospective trial registration. Conclusions: Increasing dosing to 150 mg/kg provides no benefit. Extended therapy does not reduce relapse, supporting 120 mg/kg as optimal. Persistent acne required longer treatment.

13 January 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
RIRuggero Cascio Ingurgio
Ruggero Cascio Ingurgio
AAAngela Alfano
Angela Alfano
EMElena Matteodo
Elena Matteodo
Luciano IbbaLuciano Ibba
Luciano Ibba
Luigi GargiuloLuigi Gargiulo
Luigi Gargiulo
Mario ValentiMario Valenti
Mario Valenti
Background: Psoriasis involving difficult-to-treat anatomical areas, such as the scalp, genitalia, fingernails, and palmoplantar regions, carries a disproportionate disease burden and often requires systemic therapy. In this context, real-life data comparing the long-term effectiveness of tildrakizumab 100 mg versus 200 mg in patients with difficult-to-treat psoriasis remain limited. Methods: This multicenter retrospective observational study included adult patients in three Italian dermatology centers. Global efficacy endpoints included PASI75, PASI90, PASI100, and absolute PASI ≤ 2 at weeks 16, 32, 52, and 104. Site-specific effectiveness was assessed as complete clearance (PGA = 0) in patients with baseline involvement (PGA ≥ 2) of difficult-to-treat areas. Outcomes were described by dose. Results: 183 patients were included (100 mg: n = 89; 200 mg: n = 94). Patients receiving 200 mg had higher baseline BMI and were more frequently biologic-experienced. At week 104, PASI75 was achieved by 94.2% of patients receiving 100 mg and 94.7% receiving 200 mg, while PASI90 and PASI100 were achieved by 82.7% vs. 57.9% and 48.1% vs. 47.4%, respectively. Clearance of difficult-to-treat areas improved progressively across all sites. Scalp and genital psoriasis showed higher and earlier clearance rates, whereas nail and palmoplantar psoriasis showed slower and more heterogeneous responses. No consistent dose-dependent advantage emerged, despite less favorable baseline characteristics in the 200 mg group. Conclusions: Over 104 weeks, tildrakizumab showed sustained long-term effectiveness in both global disease control and difficult-to-treat areas. The 200 mg dose, used in a more difficult-to-treat population, achieved comparable long-term outcomes, supporting dose optimization in clinical practice.

18 April 2026 in International Journal of Dermatology
Verified
Journal Article
Open access
PDF file
LBLuca Bettolini
Luca Bettolini
CMCarlo Alberto Maronese
Carlo Alberto Maronese
FDFederica Derlino
Federica Derlino
GGGiovanni Genovese
Giovanni Genovese
Chiara MoltrasioChiara Moltrasio
Chiara Moltrasio
AMAngelo Valerio Marzano
Angelo Valerio Marzano
Background: The therapeutic management of pyoderma gangrenosum (PG) is challenging. Conventional therapies, including systemic corticosteroids and cyclosporine, are limited by incomplete responses, frequent relapses, and cumulative toxicity. Emerging evidence supports a pathogenic role of the interleukin (IL)‐23/IL‐17 axis in PG, suggesting selective IL‐23 inhibition as an appealing therapeutic approach. This study assessed the effectiveness, safety, steroid‐sparing potential, and predictors of response to selective IL‐23 inhibitors in conventional treatment‐refractory PG. Methods: This multicenter retrospective study included adult patients with refractory PG or intolerant to conventional systemic therapies, treated with selective IL‐23 inhibitors (guselkumab, risankizumab, or tildrakizumab). Clinical assessments were performed at baseline and during follow‐up (1, 3, 6, 12 months, and last observation), evaluating ulcer area, number of lesions, ulcer depth, border wound bed characteristics, Investigator's Global Assessment for PG (IGAPg), and pain intensity assessed by the Numerical Rating Scale (NRS). Longitudinal changes were analyzed using non‐parametric tests for repeated measures. Results: Selective IL‐23 inhibition in 18 patients was associated with a progressive reduction in total ulcer area, significant from 1 month onward ( p = 0.0069; all subsequent p ≤ 0.0003). The number of active ulcers did not change at 1 month ( p = 0.41) but significantly decreased from Month 3 onward ( p = 0.004 to < 0.001). Ulcer depth remained unchanged at 1 month ( p = 0.41) and significantly improved from Month 3 onward ( p = 0.01–0.046). Border/perilesional inflammation and wound bed characteristics showed significant improvement at all follow‐up visits ( p = 0.0008–0.034 and p = 0.013–0.046, respectively). IGAPg score showed a significant and progressive improvement over time (all p ≤ 0.027). Pain intensity showed a significant reduction during follow‐up ( p = 0.004 to < 0.001). A significant steroid‐sparing effect was observed, with a progressive reduction in median daily prednisone‐equivalent dose during follow‐up ( p = 0.002–0.014). Guselkumab and risankizumab showed comparable efficacy ( p = 0.182). In univariate analysis, baseline ulcer depth was the only predictor of ulcer area reduction ( p = 0.039). No unexpected safety signals were observed. Conclusions: Selective IL‐23 inhibition appears to be a well‐tolerated therapeutic option for refractory PG, providing meaningful clinical improvement and a relevant steroid‐sparing effect. These findings support further controlled studies to define the role of IL‐23 inhibitors within PG treatment algorithms.

27 May 2025 in Australasian Journal of Dermatology
Verified
Journal Article
Open access
RIRuggero Cascio Ingurgio
Ruggero Cascio Ingurgio
AAA. Alfano
A. Alfano
Luigi GargiuloLuigi Gargiulo
Luigi Gargiulo
Luciano IbbaLuciano Ibba
Luciano Ibba
ANA. Narcisi
A. Narcisi
Dedee MurrellDedee Murrell
Dedee Murrell
Background: Pyoderma gangrenosum (PG) is a challenging inflammatory skin disorder. While corticosteroids offer a rapid response, their long‐term risks necessitate alternative treatments.Objective: To compare the long‐term effectiveness of biologic therapies versus systemic corticosteroids in PG management.Methods: A retrospective analysis of 15 PG patients from two centres (Sydney, Australia, and Milan, Italy) was conducted. Patients received either biologic therapies (n = 8) or corticosteroids (n = 7), with ulcer healing outcomes assessed at weeks 16, 28–32 and 54.Results: At week 16, corticosteroids led to faster ulcer reduction and re‐epithelialisation. However, biologic‐treated patients showed sustained improvement over time, supporting their role in long‐term PG management.Conclusion: While corticosteroids provide an initial advantage, biologics demonstrate gradual and sustained efficacy, suggesting a long‐term therapeutic role in PG treatment.